About
Our Story
Our People
Careers
Science
Our Science
Pipeline
Izokibep
Lonigutamab
SLRN-517
Publications
Community
Patients
Partnerships
Investors
For Investors
Press Releases
Events
News Center
News Center
Media Kit
Contact
Event

Jefferies London Healthcare Conference

Start Time:

November 16, 2023 9:00 am GMT

ACELYRIN Presentation:

November 16, 2023 9:00 am GMT

Click here for webcast

Add to Google Calendar

Add to Outlook
About ACELYRIN
ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
Learn more Arrow
About Izokibep
To date, more than 300 patients – many for up to three years – have received izokibep, a unique, antibody mimetic, interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of monoclonal antibodies. With high potency and small molecular size, izokibep can reach high drug exposure levels through a single, subcutaneous injection that monoclonal antibodies require IV administration to achieve. Additionally, the small size of izokibep – about one tenth the size of a monoclonal antibody – enables its potential to reach targeted tissues that may otherwise be inaccessible to the much larger monoclonal antibodies.
Learn more Arrow

An innovative biopharma company that identifies, acquires and accelerates the development and commercialization of transformative medicines.

Get company updates to your inbox
About us
Our Story Our People Careers News Center
Science
Our Science Pipeline Izokibep Lonigutamab SLRN-517
Community
Investors Patients Partnerships
Contact
info@acelyrin.com Contact Us Media Kit
Gradient

©2023 ACELYRIN, INC. All Rights Reserved. | ACELYRIN and the ACELYRIN logo are trademarks of ACELYRIN, INC.

Acelyrin Linkedin Acelyrin Twitter
Privacy Policy | Terms